Medicinal properties of Morus alba for the control of type 2 diabetes mellitus: a systematic review

It was based on the PRISMA Declaration. The included studies were extracted from Scopus, Pubmed, ScienceDirect, Scielo, and Google Scholar; January 2015 to July 2021, Key search terms were MeSH and DeCS: <i>Morus alba</i>, mulberry, hypoglycemic agent. The inclusion criteria were: studies in rats administered <i>Morus alba</i> leaf extracts; studies that included the dimensions of lipidemia and glycemia; studies that included indicators such as fasting glucose, postprandial glucose, glycosylated hemoglobin, triglycerides, low-density lipoproteins, total cholesterol, and insulin resistance. Exclusion criteria: studies in which <i>Morus alba</i> leaves were administered with other plants; studies with other parts of the <i>Morus alba</i> plant; proteomic studies, cancer, duplicate studies, in vitro studies, and evaluation of included studies. All included investigations were evaluated for biases. <b>Results:</b> The extracts of <i>Morus alba</i> leaves at the phytochemical level improve glucose uptake. Chlorogenic acid, isoquercitrin, and quercitrin, present in the leaves of <i>Morus alba</i> have hypoglycemic properties and an ameliorating effect on diabetic nephropathy. This leaf has pharmacological effects such as glucose absorption, insulin secretion production, antioxidant and anti-inflammatory